The global Antihypertensive Drugs market size is expected to be worth around US$ 41 billion by 2030, according to a new report by Nova one advisor.
The global Antihypertensive Drugs market size was valued at US$ 30.8 billion in 2021 and is anticipated to grow at a CAGR of 3.45% during forecast period 2022 to 2030.
Overview of Antihypertensive Drugs Market
Antihypertensive medications are used to treat high blood pressure. Different types of antihypertensive drugs are available in the market. These help lower blood pressure. Some remove excess fluid and salt from the body, while others help relax and widen blood vessels or slow the heart rate. A person could respond better and experience fewer side effects to one drug than to another. Some patients require more than one antihypertensive agent to lower blood pressure.
Hypertension is a preventable risk factor for atherosclerotic disease and ischemic heart disease. A number of patients maintain suboptimal blood pressure control despite the availability of modern and effective antihypertensive drugs. Most hypertensive patients require a combination of antihypertensive agents to achieve treatment goals. Under combination therapy, another class of blood pressure medication is added to the first drug to increase its effectiveness. The antihypertensive drugs market has reasonably high unmet demand, which indicates the lack of effective products. This presents significant opportunities for new entrants to capitalize on the unmet needs, largely due to poor patient compliance with products currently available in the market.
Trends in antihypertensive medication in stroke survivors could provide important insights into gaps in secondary prevention that can guide improved interventions in the future. Healthcare companies are increasing R&D in the field of genomics and resistant hypertension treatment to gain a competitive edge over other market players.
Launch of New Disease-modifying Therapies to Drive Global Antihypertensive Drugs Market
Innovative antihypertensive drugs and drug therapies are expected to offer favorable outcomes, as these effectively target disease progression. The current scenario in the global antihypertensive drugs market is expected to change due to the launch of new therapies for diseases such as angiotensin II receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, and calcium channel blockers (CCB) during the forecast period.
Currently, physicians prescribe fewer diuretics and beta-blockers, common first-line agents for hypertension, and more ACE and CHF inhibitors. ACE inhibitors reduce mortality and morbidity in cardiovascular patients; however, this is not true for CCBs. If control is not available on beta
blockers, diuretics, or ACE inhibitors, short-acting CHFs should be avoided and alternatives should be considered. Unlike ACE inhibitors, ARBs do not cause cough. Therefore, launch of innovative drug/therapeutic molecules with disease-modifying properties and improved efficacy and safety is expected to drive the global antihypertensive drugs market in the next few years.
Promising Products in Pipeline to Boost Demand for Antihypertensive Drugs
Treatments for hypertension are relatively potent. Several drugs are being studied in clinical trials, including those with disease-modifying properties, better safety, and effectiveness, which can reduce disease progression significantly.
Launch of new products with improved efficiency and safety is expected to drive the market. Bayer's candesartan cilexetil/nifedipine (phase III), Boryung Pharmaceuticals' fimasartan/amlodipine (phase III), and Takeda Pharmaceuticals' diuretic azilsartan/amlodipine/hydrochlorothiazide (phase III) are some of the drugs under development.
